Combination exposure, tumor growth and vascular support

Mechanism untreated

Authored fixed-concentration mechanism experiment; no clinical dose or observed patient is represented.

Readouts

Tumor total · cell

Tumor total over the selected simulation window.

Tumor relative change · dimensionless

Tumor relative change over the selected simulation window.

Quality fraction · dimensionless

Quality fraction over the selected simulation window.

Ram · ng/mL

Ram over the selected simulation window.

Pac · ng/mL

Pac over the selected simulation window.

Study purpose

• How do the model's key biological readouts change under mechanism untreated?

Assumptions

• These are authored mathematical concentration experiments, not clinical mg/kg or mg/m2 administrations.
• Tumor and vascular-support variables use absolute cell-equivalent coordinates; the supplied initial scale is authored and is not an observed patient.
• Four varying PD rates use arithmetic midpoints of the final reported ranges; these are not fitted individual or population-typical estimates.
• Ramucirumab elimination follows the declared CL/V1 day-clock convention. Ab and At retain the literal source reciprocal-rate equations; At is not a qualified physical tissue concentration.
• All seven selected source identities remain disabled: four primary references and three clinical/adaptive contexts awaiting source bindings.
• The fixed delayed-concentration experiment does not implement the published adaptive quality-of-vasculature controller.
• Clinical dose conversion, final virtual-patient reconstruction, calibration, Kaplan–Meier prediction and clinical interpretation remain held.
• Parameters and initial conditions are frozen together; no independent baseline or cell-scale edits are supported.
• S and S+U must remain positive. No clamps or silent state normalization modify the published equations.